PFE Dec 2025 37.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:32AM EST. Market open.
| Previous close | 1.4200 |
| Open | 1.6000 |
| Bid | 1.3400 |
| Ask | 1.8900 |
| Strike | 37.50 |
| Expiry date | 2025-12-19 |
| Day's range | 1.6000 - 1.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.5k |
ZacksRoche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B
Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
ZacksAltimmune (ALT) Rises 83% on Successful Phase II Obesity Study
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
ZacksPfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.
© 2023 Yahoo. All rights reserved.